RXi Pharmaceuticals granted Chinese patent
Courtesy of RXi Pharmaceuticals Corp.
RXi Pharmaceuticals Corp., a clinical-stage biotechnology company based in Marlborough, has been granted a Chinese patent for the composition and methods of use for compounds that may be used to treat dermal scarring, the company announced Monday.
The patent covers RXI-109 and other connective tissue growth factor (CTGF) targeting self-delivering RNAi compounds (sd-rxRNA®) for the treatment of fibrotic disorders, including skin fibrosis, according to the company. These compounds may be used to treat dermal scarring, which China is a significant market for, according to RXi Pharmaceuticals.
"We are pleased with the issuance of this core patent which covers RXI-109 in China," Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, said in a statement. "Not only does this patent further strengthen our intellectual property portfolio, it also expands regional out-licensing and partnering opportunities available with our self-delivering platform. This comes at an important time as we accelerate our business development efforts.”
The company recently cut losses and raised cash as it continues to advance its clinical and preclinical pipeline.
WBJ Web Partners
Most Recent
Most Recent
0 Comments